China SXT Pharmaceuticals Inc（SXTC）の財務SXTCChina SXT Pharmaceuticals Inc

China SXT Pharmaceuticals Inc (SXTC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Regular TCMP, accounting for 52.7% of total sales, equivalent to $520.76K. Other significant revenue streams include Advanced TCMP and Others . Understanding this composition is critical for investors evaluating how SXTC navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, China SXT Pharmaceuticals Inc maintains a gross margin of 16.23%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1011.69%, while the net margin is -1016.46%. These profitability ratios, combined with a Return on Equity (ROE) of -50.30%, provide a clear picture of how effectively SXTC converts its operational activities into shareholder value.

In the context of the broader market, SXTC competes directly with industry leaders such as RDHL and SILO. With a market capitalization of $1.37M, it holds a significant position in the sector. When comparing efficiency, SXTC's gross margin of 16.23% stands against RDHL's 100.00% and SILO's -14.77%. Such benchmarking helps identify whether China SXT Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The forward P/E ratio is 0, indicating no earnings forecast, while the price-to-sales ratio stands at 1.623, suggesting the stock is not undervalued based on sales. The company has a negative P/E ratio of -0.214227, indicating losses, and a price-to-book ratio of 0.062192, which is extremely low and suggests the stock is trading well below its book value.